KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Non-Current Assets: 2009-2024

Historic Other Non-Current Assets for Acadia Pharmaceuticals (ACAD) over the last 15 years, with Dec 2024 value amounting to $8.8 million.

  • Acadia Pharmaceuticals' Other Non-Current Assets rose 7.99% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 7.99%. This contributed to the annual value of $8.8 million for FY2024, which is 51.99% up from last year.
  • As of FY2024, Acadia Pharmaceuticals' Other Non-Current Assets stood at $8.8 million, which was up 51.99% from $5.8 million recorded in FY2023.
  • Acadia Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $8.8 million during FY2024, with a 5-year trough of $5.8 million in FY2020.
  • Over the past 3 years, Acadia Pharmaceuticals' median Other Non-Current Assets value was $5.8 million (recorded in 2023), while the average stood at $6.8 million.
  • Data for Acadia Pharmaceuticals' Other Non-Current Assets shows a peak YoY surged of 51.99% (in 2024) over the last 5 years.
  • Over the past 5 years, Acadia Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $5.8 million in 2020, then remained steady at $5.8 million in 2021, then remained steady at $5.8 million in 2022, then remained steady at $5.8 million in 2023, then skyrocketed by 51.99% to $8.8 million in 2024.